Drug & intervention

Stalevo

RxCUI 1372713

Clinical trials5

Recruiting0

Related conditions2

Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

5 shown

Clinical Study of Stalevo in the Treatment of Early Parkinson's DiseaseNCT04952194 · 2022-01-01

Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC)NCT02764125 · 2016-04-08

Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor FluctuationsNCT01766258 · 2011-05-01

Study to Evaluate Initiation of Stalevo in Early Wearing-offNCT00462007 · 2006-09-01

An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)NCT00200447 · 2004-03-01

Conditions being studied

Parkinson's Disease4 Parkinson Disease1

Research locations

BerlinGermany1 BochumGermany1 BudapestHungary1 CologneGermany1 DresdenGermany1 HamburgGermany1 HangzhouZhejiang, China1 RigaLatvia1 TübingenGermany1 TurkuFinland1 UlmGermany1

Leading sponsors

Orion Corporation, Orion Pharma3 Molecular NeuroImaging1 Second Affiliated Hospital, Zhejiang University, School of Medicine1

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.